ライフサイエンスコーパス: antireflux

1 One of the proposed mechanisms for its antireflux action is that it reduces lower esophageal sp

2 Based on this mechanism of the antireflux actions of fundoplication, it might be possib

3 formed with low variation; MIS appendectomy, antireflux, and bariatric operations with medium variati

4 d: cholecystectomy, appendectomy, colectomy, antireflux, and bariatric.

5 c antireflux therapies aiming at creating an antireflux barrier and reducing or eliminating the need

6 iculties in objectively proving an effective antireflux barrier.

7 ux disease or to determine the necessity for antireflux intervention.

8 toms suggestive of GER who do not respond to antireflux management may need to be treated for eosinop

9 nction as well as a compromise of the native antireflux mechanism.

10 ageal acid exposure to a greater extent than antireflux medication (eg, proton pump inhibitors).

11 eflux recurrence when studying recurrence by antireflux medication (HR, 1.04; 95% CI, 0.90-1.21) and

12 of symptoms necessitating reintroduction of antireflux medication (ie, "intention to treat") and pos

13 was recurrence of reflux, defined as use of antireflux medication (proton pump inhibitors or histami

14 x recurrence; 393 (83.6%) received long-term antireflux medication and 77 (16.4%) underwent secondary

15 t difference between the need for restarting antireflux medication between both groups because of rec

16 ageal adenocarcinoma to a larger degree than antireflux medication in patients with Barrett's esophag

17 bitor test results, long-term treatment with antireflux medication is warranted.

18 defined as 6 months or more of postoperative antireflux medication or secondary antireflux surgery.

19 ery compared with nonoperated patients using antireflux medication, but rather increased (adjusted HR

20 gn disease course but less responsiveness to antireflux medication.

21 ere compared with nonoperated patients using antireflux medication.

22 f esophageal adenocarcinoma than those using antireflux medication.

23 g that nonerosive GERD responds less well to antireflux medication.

24 37 surgical patients reported that they used antireflux medications regularly (P<.001).

25 of obesity; common infectious diagnoses and antireflux medications were not.

26 isolated to the esophagus despite the use of antireflux medications.

27 ant center provided samples before and after antireflux Nissen fundoplication surgery.

28 records of 130 children undergoing a second antireflux operation for recurrent GER from January 1985

29 The addition of a Collis gastroplasty to an antireflux operation is an effective strategy in patient

30 tment of esophageal stricture and subsequent antireflux operations, SF-36 standardized physical and m

31 tic endoscopy, for example, may soon include antireflux operations.

32 ion after invasive foregut intervention (ie, antireflux or bariatric intervention).

33 Aggressive antireflux pharmacotherapy and, sometimes, surgery help

34 in patients with asthma or stridor following antireflux pharmacotherapy or surgery.

35 on appropriate indications for a concurrent antireflux procedure as well as alternatives to fundopli

36 hageal acid exposure, and the addition of an antireflux procedure is not required.

37 A safe and effective endoscopic antireflux procedure remains elusive.

38 n case series, many surgeons believe that an antireflux procedure should be added to the Heller myoto

39 views the most notable results of endoscopic antireflux procedure studies published in 2005.

40 Inclusion of an antireflux procedure, incidence of subsequent hernia rec

41 Laparoscopic myotomy, when combined with an antireflux procedure, provided better symptom relief (90

42 verticulopexy with esophageal myotomy and an antireflux procedure.

43 ux symptoms was unrelated to inclusion of an antireflux procedure.

44 bdominal exploration (nontrauma) (4.4%), and antireflux procedures (3.6%).

45 .2% MIS), vagotomy (1.8% MIS), and pediatric antireflux procedures (35.9% MIS); P < .001.

46 my 6.5%; colectomy 22.8%; gastrectomy 23.4%; antireflux procedures 23.4%; pancreatic resection 37.4%;

47 s the available literature on new endoscopic antireflux procedures along with other advances that giv

48 Antireflux procedures are most commonly performed in chi

49 Feeding access and associated antireflux procedures continue to be some of the most co

50 Additional endoscopic antireflux procedures have been introduced, although the

51 Endoscopic antireflux procedures have generated much interest among

52 ion, (6) chemopreventive strategies, and (7) antireflux procedures in the prevention of progression i

53 As such, antireflux procedures should address both for optimal im

54 n that many surgeons will not perform enough antireflux procedures to become familiar with its diagno

55 lative contribution of critical steps during antireflux procedures to the functional integrity of the

56 Sac removal, crural repair, and antireflux procedures were performed (72 Nissen, 27 Coll

57 rial was performed to determine which of two antireflux procedures, a complete wrap (Nissen) or a 200

58 antly open to MIS approach for appendectomy, antireflux procedures, thoracic wedge resection, and par

59 Fifteen patients underwent antireflux procedures.

60 ization should be a part of all laparoscopic antireflux procedures.

61 A study on an antireflux stent will not measurably change the current

62 Antireflux surgery (fundoplication) counteracts gastroes

63 (HR = 1.21, 95% CI 0.96-1.51), or secondary antireflux surgery (HR = 1.28, 95% CI 1.05-1.54), but ra

64 .06-2.77), and low hospital annual volume of antireflux surgery (HR = 1.32, 95% CI 1.04-1.67).

65 (HR, 1.04; 95% CI, 0.90-1.21) and secondary antireflux surgery (HR, 0.91; 95% CI, 0.75-1.10) separat

66 gus (BE) are frequently offered laparoscopic antireflux surgery (LARS) to treat symptoms.

67 common in the learning curve of laparoscopic antireflux surgery (LARS).

68 n regarding "success" rates for laparoscopic antireflux surgery (LARS).

69 Among all 2655 patients who underwent antireflux surgery (median age, 51.0 years; interquartil

70 The corresponding rates after secondary antireflux surgery (n = 1 618) were 0.19% (n = 3) and 6.

71 2.06-43.32; P = 0.0005) and necessitate more antireflux surgery (OR 2.12; 95% CI 1.06-4.24; P = 0.034

72 ectomy (OR: 2.0; 95% CI: 1.2-3.3; P < 0.01), antireflux surgery (OR: 24.7; 95% CI: 2.6-580.9; P < 0.0

73 ithout fistula (P = 0.03), previous multiple antireflux surgery (P = 0.04), esophageal dilation (P =

74 population, EAC risk did not decrease after antireflux surgery [SIR 4.90 (95% CI 3.62-6.47) 1-<5 yea

75 population, EAC risk did not decrease after antireflux surgery [SIR 4.90 (95% CI 3.62-6.47) 1-<5 yea

76 were particularly decreased >10 years after antireflux surgery [SIR = 0.28 (95% CI 0.08-0.72) and HR

77 mates were further decreased >10 years after antireflux surgery [SIR = 0.48 (95% CI 0.26-0.80) and HR

78 cell carcinoma (n = 39) were decreased after antireflux surgery [SIR = 0.62 (95% CI 0.44-0.85) and HR

79 were particularly decreased >10 years after antireflux surgery [SIR=0.28 (95% CI 0.08-0.72) and HR=0

80 mates were further decreased >10 years after antireflux surgery [SIR=0.48 (95% CI 0.26-0.80) and HR=0

81 s cell carcinoma (n=39) were decreased after antireflux surgery [SIR=0.62 (95% CI 0.44-0.85) and HR=0

82 ing 2655 patients who underwent laparoscopic antireflux surgery according to the Swedish Patient Regi

83 Since 1991, all patients undergoing antireflux surgery across 2 hospital sites have been fol

84 Anatomic fundoplication failure occurs after antireflux surgery and may be more common in the learnin

85 There was no difference in EAC risk between antireflux surgery and medical treatment in GERD patient

86 Laparoscopic antireflux surgery and repair of small hiatal hernias ar

87 risk of reflux recurrence after laparoscopic antireflux surgery and to identify risk factors for recu

88 up, 53 patients (76%) underwent laparoscopic antireflux surgery because of symptoms refractory to med

89 ased case-control study was nested within an antireflux surgery cohort from the Swedish Patient Regis

90 From 14,102 patients in the total antireflux surgery cohort, 55 cases and 240 controls wer

91 s not decreased in patients having undergone antireflux surgery compared with nonoperated patients us

92 EAC risk remained elevated in patients after antireflux surgery compared with the background populati

93 otal of 345 patients undergoing laparoscopic antireflux surgery completed at least one questionnaire

94 e overrepresented among patients who despite antireflux surgery develop esophageal adenocarcinoma.

95 atients with Barrett's esophagus who undergo antireflux surgery do not seem to have a lower risk of e

96 The EAC risk after antireflux surgery does not seem to revert to that of th

97 Primary laparoscopic antireflux surgery due to gastroesophageal reflux diseas

98 Antireflux surgery for gastro-esophageal reflux disease

99 identify adults in England receiving primary antireflux surgery for GERD in 2000 to 2012 with follow-

100 ons were made against antacid medication and antireflux surgery for the treatment of IPF.

101 sideration should be given to more effective antireflux surgery for transplants, with subsequent test

102 that preventing gastroesophageal reflux with antireflux surgery halts the progression of BE, often be

103 These findings suggest that laparoscopic antireflux surgery has an overall favorable safety profi

104 Antireflux surgery has become more popular with advanced

105 Reflux recurrence after laparoscopic antireflux surgery has not been assessed in a long-term

106 Antireflux surgery has the potential to stop reflux and

107 rvention and 59.5% medical therapy following antireflux surgery in England.

108 Antireflux surgery in patients with Barrett's esophagus

109 ts who had primary laparoscopic or secondary antireflux surgery in the 5 Nordic countries in 2000-201

110 Among 2005 patients who underwent primary antireflux surgery in the Clinical Practice Research Dat

111 First, EAC risk after antireflux surgery in the cohort was compared with the c

112 he only significant drawback is the need for antireflux surgery in the first years of life.

113 Among 22,377 patients who underwent primary antireflux surgery in the Hospital Episode Statistics da

114 Concerns about laparoscopic antireflux surgery include the frequent appearance of tr

115 As a result, laparoscopic antireflux surgery is a common surgical procedure.

116 Studies continue to show that laparoscopic antireflux surgery is a cost-effective treatment option

117 tion, the barium esophagram before and after antireflux surgery is a critical examination in patients

118 Laparoscopic antireflux surgery is a very effective and long-lasting

119 Laparoscopic [correction of Laparascopic] antireflux surgery is an alternative strategy, but neith

120 Laparoscopic antireflux surgery is an effective therapy for patients

121 Antireflux surgery is an effective treatment of gastroes

122 Antireflux surgery is associated with regression of Barr

123 The management of patients who fail antireflux surgery is complex and not well codified.

124 e aim of this study was to determine whether antireflux surgery is more effective in producing loss o

125 Antireflux surgery is often necessary, but a 10% failure

126 LARS has increased the frequency with which antireflux surgery is performed for the treatment of gas

127 Loss of intestinal metaplasia after antireflux surgery is rare in patients with Barrett's, b

128 Antireflux surgery is safe and effective in patients wit

129 The entity of the short esophagus in antireflux surgery is seldom discussed in the laparoscop

130 GERD responds less well than erosive GERD to antireflux surgery is unclear.

131 and characterization of hypomotility before antireflux surgery may be less important than systematic

132 Antireflux surgery may decrease the risk of laryngeal sq

133 BRAVO wireless pH monitoring, suggests that antireflux surgery may halt the progression of Barrett's

134 Higher hospital volume of primary antireflux surgery may not decrease risk of endoscopic o

135 Antireflux surgery may prevent EAC better than medical t

136 To assess the long-term efficacy of antireflux surgery on Barrett's esophagus (BE) using BRA

137 flux-reducing medication (e.g., baclofen) or antireflux surgery or on dampening visceral hypersensiti

138 Second, cancer risk among antireflux surgery patients was compared to nonoperated

139 sease (GERD) increases EAC risk, but whether antireflux surgery prevents EAC is uncertain.

140 We examined the hypothesis that antireflux surgery prevents esophageal adenocarcinoma to

141 The aim of this study was to clarify whether antireflux surgery prevents laryngeal and pharyngeal squ

142 A question exists as to whether antireflux surgery reduces this risk.

143 ght explain the lack of protective effect of antireflux surgery regarding risk of developing esophage

144 nd risk factors of short-term outcomes after antireflux surgery remain largely unknown.

145 sophageal motor dysfunction to outcomes from antireflux surgery remains incompletely understood.

146 This study suggests that antireflux surgery should not be advised with the expect

147 Studies evaluating ileal pouch formation and antireflux surgery showed conflicting results.

148 phageal disease allows the surgeon to tailor antireflux surgery to esophageal body function and follo

149 y compared with no therapy and compared with antireflux surgery to prevent progression in BE.

150 agus, and 2 studies comparing EAC risk after antireflux surgery to the background population.

151 The pooled IRR in patients after antireflux surgery was 0.76 (95% CI 0.42-1.39) compared

152 Laparoscopic antireflux surgery was associated with a relatively high

153 First, cancer risk after antireflux surgery was compared to the expected risk in

154 Hospital volume of antireflux surgery was not associated with risk of reflu

155 Antireflux surgery was performed in 18 patients (17%).

156 Primary antireflux surgery was performed on 100 consecutive pati

157 prospectively collected research database of antireflux surgery was performed to identify all patient

158 The outcome of antireflux surgery was studied in 97 patients with Barre

159 n, endoscopic re-intervention, and secondary antireflux surgery were 1.2%, 4.6%, and 7.0%, respective

160 Patients who underwent antireflux surgery were compared with nonoperated patien

161 with BE and at least 5 years follow up after antireflux surgery were identified.

162 classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews a

163 ophageal peristalsis undergoing laparoscopic antireflux surgery were prospectively studied.

164 entified 10 studies comparing EAC risk after antireflux surgery with nonoperated GERD patients, inclu

165 CIs, compared EAC risk in GERD patients with antireflux surgery with those with nonsurgical treatment

166 patients who underwent primary laparoscopic antireflux surgery, 17.7% experienced recurrent gastroes

167 on, 8% were undernourished, 41% had received antireflux surgery, and 41% presented with GERD symptoms

168 2011 using the keywords achalasia, myotomy, antireflux surgery, and fundoplication.

169 laparoscopic appendectomy, cholecystectomy, antireflux surgery, and gastric bypass between 2002 and

170 ss level who underwent open cholecystectomy, antireflux surgery, and gastric bypass had a greater ris

171 Antireflux surgery, as opposed to medical therapy, may i

172 motility assessments in patients undergoing antireflux surgery, as peristaltic features do not solel

173 or sex, age, comorbidity, hospital volume of antireflux surgery, calendar year, and country.

174 likely to have recurrent reflux after their antireflux surgery, compared with those who had not (OR:

175 eration should not alter the indications for antireflux surgery, especially for patients with atypica

176 After antireflux surgery, highly variable rates of recurrent g

177 After antireflux surgery, most patients with Barrett's enjoy l

178 patients who underwent primary laparoscopic antireflux surgery, postoperative 90-day mortality and 9

179 nts and a median follow-up of 12 years after antireflux surgery, the frequencies of 30-day re-interve

180 ageal adenocarcinoma more than 5 years after antireflux surgery, whereas randomly selected controls w

181 ported high rates of reflux recurrence after antireflux surgery, which may have contributed to a decl

182 adjusted for age, sex, comorbidity, type of antireflux surgery, year of surgery, and country.

183 4,230 GERD patients, 47,016 (5.8%) underwent antireflux surgery.

184 ection and surgical experience in successful antireflux surgery.

185 be approximately 10% of patients undergoing antireflux surgery.

186 al metaplasia of the esophagus or cardia had antireflux surgery.

187 induced asthma responds convincingly only to antireflux surgery.

188 equivalent in efficacy to open techniques of antireflux surgery.

189 Of these, 542 (1.6%) had undergone antireflux surgery.

190 operative antireflux medication or secondary antireflux surgery.

191 Sweden for patients having undergone primary antireflux surgery.

192 t be used as an argument for abstaining from antireflux surgery.

193 tcomes of primary laparoscopic and secondary antireflux surgery.

194 the long-term risk development of EAC after antireflux surgery.

195 uiring long-term medication use or secondary antireflux surgery.

196 edication and 77 (16.4%) underwent secondary antireflux surgery.

197 ptor antagonists for >6 months) or secondary antireflux surgery.

198 ss index (BMI), tobacco smoking, and type of antireflux surgery.

199 d better elucidate those who will respond to antireflux surgery.

200 pport for any cancer-protective effect after antireflux surgery.

201 regarding age, sex, and calendar year of the antireflux surgery.

202 n, endoscopic re-intervention, and secondary antireflux surgery.

203 reatment can be achieved with medication and antireflux surgery; however the possible preventive effe

204 Several endoscopic antireflux therapies aiming at creating an antireflux ba

205 reports may show some advantage of surgical antireflux therapy in reducing the risk of adenocarcinom

206 antly improves quality of life, and surgical antireflux therapy may gradually cause regression of the

207 scale scores, and overall satisfaction with antireflux therapy.

208 re sensitive tool for judging the success of antireflux therapy.

209 If EER were a cause or cofactor of ITH, antireflux treatment can be considered prior to surgical

210 Antireflux treatment is recommended to reduce esophageal